Obagi Medical partners with Moxie to enhance aesthetic practices through the ALOHA Program, focusing on innovative skincare solutions.
Quiver AI Summary
Obagi Medical has announced a strategic partnership with Moxie as part of its ALOHA Program, which focuses on Hyaluronic Acid products. Moxie, known for its comprehensive software and support for med spa entrepreneurs, will help assess the integration of Obagi® saypha® MagIQ™ filler across various aesthetic practices. The collaboration aims to collect standardized data on clinical performance and patient experience to drive satisfaction and improve business success. Moxie's CEO emphasized their commitment to empowering aesthetic entrepreneurs with innovative tools, while Obagi's U.S. General Manager highlighted the partnership's potential to elevate patient care. The new filler, developed by Croma-Pharma GmbH, promises natural-looking results through advanced technology. Initial findings from the program will be shared at industry events to showcase its effectiveness in med spa environments.
Potential Positives
- Obagi Medical has formed a strategic partnership with Moxie, enhancing its ALOHA Program through Moxie's expertise in operational tools and support for aesthetic practices.
- The collaboration aims to generate meaningful real-world evidence on the integration of Obagi's saypha® MagIQ™ filler into aesthetic workflows, promoting data-driven insights and optimized practices.
- The program's focus on clinical performance and patient experience is designed to elevate patient care and drive satisfaction, loyalty, and consistent results in the aesthetic market.
- Obagi Medical has been recognized as the fastest-growing professional skincare brand in the U.S. in 2024, highlighting its strong market presence and commitment to innovative skincare solutions.
Potential Negatives
- The announcement heavily relies on a partnership with Moxie, which may raise concerns about Obagi's autonomy and ability to drive growth independently.
- The collaboration focuses on a new injectable, saypha® MagIQ™, indicating a potential reliance on external innovations, which may not resonate well with investors seeking organic growth.
- There is an emphasis on data-driven assessments, implying that prior performance metrics may not have met expectations or that there's a need for validation.
FAQ
What is the ALOHA Program by Obagi Medical?
The ALOHA Program utilizes real-world evaluation to assess Obagi’s hyaluronic acid products in aesthetic practices, enhancing patient outcomes and business success.
Who is Moxie in relation to Obagi Medical?
Moxie is a strategic partner selected for its expertise in supporting med spa entrepreneurs with software, marketing, and operational solutions to optimize practices.
What technology does Obagi’s saypha® MagIQ™ use?
Obagi’s saypha® MagIQ™ utilizes proprietary MACRO Core Technology for stable, natural-looking results with high performance in aesthetic procedures.
How does the ALOHA Program benefit aesthetic practices?
The program provides integrated Obagi protocols and operational tools to drive satisfaction, loyalty, and consistent results among participating aesthetic practices.
Where can I find more information about Obagi Medical?
More details about Obagi Medical and its products can be found on their official website at https://www.obagi.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$WALD Hedge Fund Activity
We have seen 33 institutional investors add shares of $WALD stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ZENO EQUITY PARTNERS LLP removed 3,082,963 shares (-20.1%) from their portfolio in Q3 2025, for an estimated $6,104,266
- NAMAN CAPITAL LTDA removed 776,722 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,537,909
- TRUXT INVESTMENTOS LTDA. removed 757,700 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,500,246
- UBS GROUP AG removed 745,165 shares (-88.9%) from their portfolio in Q4 2025, for an estimated $1,400,910
- MILESTONES ADMINISTRADORA DE RECURSOS LTDA. added 225,677 shares (+10.3%) to their portfolio in Q3 2025, for an estimated $446,840
- AMITELL CAPITAL PTE LTD removed 210,069 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $415,936
- BLACKROCK, INC. added 104,203 shares (+5.5%) to their portfolio in Q3 2025, for an estimated $206,321
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$WALD Analyst Ratings
Wall Street analysts have issued reports on $WALD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 01/14/2026
- Canaccord Genuity issued a "Buy" rating on 11/25/2025
To track analyst ratings and price targets for $WALD, check out Quiver Quantitative's $WALD forecast page.
$WALD Price Targets
Multiple analysts have issued price targets for $WALD recently. We have seen 3 analysts offer price targets for $WALD in the last 6 months, with a median target of $3.0.
Here are some recent targets:
- Sydney Wagner from Jefferies set a target price of $2.0 on 01/14/2026
- Susan Anderson from Canaccord Genuity set a target price of $4.0 on 11/25/2025
- Dana Telsey from Telsey Advisory Group set a target price of $3.0 on 11/25/2025
Full Release
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Moxie as a strategic partner in the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Moxie was selected for its expertise in providing all-in-one software, marketing, coaching, and compliance solutions that help med spa entrepreneurs launch, scale, and optimize their practices with predictable growth, profitability, and a foundation of clinical and operational excellence.
Through this real-world evaluation collaboration, Moxie will facilitate a structured assessment of Obagi® saypha® MagIQ™ across its network of supported aesthetic practices. The program will leverage Moxie’s strengths in data-driven insights, operational tools, and expert coaching to generate meaningful real-world evidence on the filler’s integration into scalable aesthetic workflows.
“At Moxie, we’re dedicated to empowering aesthetic practice entrepreneurs with the tools, support, and strategies needed to build thriving, compliant practices,” said Kamau Massey, CEO of Moxie. “Obagi’s ALOHA Program resonates with our focus on innovation and real-world results, allowing us to help our partners incorporate advanced injectables like saypha® MagIQ™ alongside comprehensive skincare protocols to enhance patient outcomes and business success.”
The ALOHA Program evaluates both clinical performance and patient experience while equipping providers with integrated Obagi protocols to drive satisfaction, loyalty, and consistent results. Standardized data will be collected across participating Moxie-supported practices, with initial findings to be shared at upcoming Moxie events and presented at key industry conferences to demonstrate the impact of this new injectable in technology-enabled med spa environments.
“The Moxie opportunity is unique and highlights Obagi’s Aesthetics for All™ ethos with a focus on supporting practices of all sizes and shapes," said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA partnership with Moxie combines cutting-edge software and coaching with our skincare and injectables expertise in addition to targeted marketing efforts to empower practices and elevate patient care in a rapidly evolving market.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website,
https://www.obagi.com
.
About Moxie
Moxie is the clinical-grade operating system built exclusively for aesthetic medicine, helping ambitious practice owners scale without compromise. From charting and compliance to marketing, finance, and coaching, Moxie brings every operational need under one roof—so practices can grow safely, sustainably, and with integrity. Learn more at
joinmoxie.com
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit:
https://ir.waldencast.com
.
Media Contact:
[email protected]
Source: Waldencast plc
¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
